Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454103
Status:
COMPLETED
Last Update Posted:
2010-08-18
First Post:
2007-03-28
Brief Title:
Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy
Sponsor:
University of Wuerzburg
Organization:
University of Wuerzburg
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The improvement of conventional imaging techniques has led to an increased detection rate of different adrenal tumors Since those tumors can belong to a variety of entities the therapeutic consequences also show considerable variation In order to definitely determine the type of tumor invasive procedures like CT guided biopsies are often required which could be avoided by a tumor specific imaging method The presently available scintigraphic procedures are either time consuming and lead to high radiation exposure or are technically demanding The steroidogenic enzymes CYP11B1 11ß-hydroxylaseand CYP11B2 aldosterone synthaseare expressed exclusively in the adrenal cortex and therefore represent suitable targets for a specific imaging technique In our project we evaluate 123I-Iodometomidate which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None